Enhanced Anti-Inflammatory Peptide Compositions and Systems

This invention relates to improved anti-inflammatory peptide compositions and systems, enhancing the treatment of dermal related inflammatory diseases through targeted delivery and synergistic effects.

The original patent disclosed anti-inflammatory peptides and compositions, but had limitations in terms of delivery and efficacy. The new inventive concept addresses these limitations by introducing nanoparticle or liposome carriers, conjugating peptides with targeting moieties, and combining peptides with anti-inflammatory agents.

The inventive concept comprises a system for treating dermal related inflammatory diseases, featuring a composition of the isolated peptide of SEQ ID NO: 1 and a carrier, such as a nanoparticle or liposome. This targeted delivery approach enhances the anti-inflammatory effect of the peptide. Additionally, the peptide can be conjugated with a targeting moiety specific to inflammatory cells, further improving its efficacy. The inventive concept also encompasses pharmaceutical compositions combining the isolated peptide with anti-inflammatory agents, such as corticosteroids or non-steroidal anti-inflammatory drugs, to achieve synergistic effects. Furthermore, a kit for treating dermal related inflammatory diseases can be provided, comprising the isolated peptide, a carrier, and instructions for administration. The inventive concept also includes a method for determining the efficacy of the peptide in treating dermal related inflammatory diseases by measuring the expression level of an inflammatory marker.

The new claims introduce novel carriers, conjugation methods, and pharmaceutical compositions that enhance the delivery and efficacy of the original anti-inflammatory peptides. These improvements are non-obvious and provide a significant advance over the original patent.

Alternative embodiments of the inventive concept could include using different types of carriers, such as micelles or dendrimers, or conjugating the peptide with different targeting moieties. Additionally, the pharmaceutical composition could be formulated for different routes of administration, such as topical or injectable forms.

The enhanced anti-inflammatory peptide compositions and systems have significant commercial potential in the treatment of dermal related inflammatory diseases, such as psoriasis, burns, and sunburns. The target industries include pharmaceutical, biotechnology, and dermatology companies, with potential market applications in human health and veterinary care.